STAT+ reported that China is tightening clinical-trial oversight, even as the US seeks ways to match China’s speed in bringing studies forward. The article focuses on how investigator-initiated trials (ITT) have been scrutinized for transparency and patient safety tradeoffs, with the adjustment signaling a potential slowdown in the operational model that previously enabled rapid biomedical scaling.